rs281864938
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000249.4(MLH1):c.1946delC(p.Pro649LeufsTer12) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000249.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 89954). This premature translational stop signal has been observed in individuals with Lynch syndrome with high tumor microsatellite instability (PMID: 10521294, 11291077, 14645426, 16116158, 19224586, 20215533). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Pro649Leufs*12) in the MLH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1946delC pathogenic mutation, located in coding exon 17 of the MLH1 gene, results from a deletion of one nucleotide at nucleotide position 1946, causing a translational frameshift with a predicted alternate stop codon (p.P649Lfs*12). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This mutation was identified in conjunction with a MSH6 missense alteration in a proband with MSI-H endometrial cancer (Wu Y et al. Am. J. Hum. Genet. 1999 Nov;65:1291-8) and has since been reported in individuals meeting Amsterdam criteria with MSI-H tumors and/or absent MLH1 staining by IHC analysis (Berends MJ et al. J. Clin. Oncol. 2003 Dec;21:4364-70; Niessen RC et al. Gut 2006 Dec;55:1781-8; Yap HL et al. Fam. Cancer, 2009 Aug;8:85-94). Additionally, this mutation was seen in a male breast cancer patient whose breast tumor demonstrated loss of MLH1 and PMS2 protein expression by IHC (Walsh MD et al. Clin. Cancer Res. 2010 Apr;16:2214-24). Of note, this alteration is also designated as p.P649fs and Pro649fsX661 in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at